Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the safety of 2 different doses of the
investigational use of an allergy medication (Astepro Nasal Spray) in the treatment of
allergic rhinitis (AR). This is an open-label study; that is, parent and child will know
which group each is in.